CDK9

Kronos Bio Announces Participation in Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 22, 2022
KRON, Research, SYK, SAN, Patient, MYC, Cancer, Conference, CDK9, Pharmaceutical industry

ET; and

Key Points: 
  • ET; and
    Evercore ISIs 5th Annual HealthCONx on Thursday, December 1, 2022, at 1 p.m.
  • The fireside chats will be available on the Investors & Media section of the companys website at www.kronosbio.com .
  • Kronos Bio is a biopharmaceutical company that is advancing two investigational compounds in clinical trials for patients with cancer.
  • Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass.

SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 14, 2022
MSD, NEPC, Clinical trial, Survival, Senior, ASH, Cancer, Acquisition, D, Memorial Sloan Kettering Cancer Center, MD, Webcast, New Board, CDK9, Acute myeloid leukemia, Drug development, WT1, GPS, Research, American Society of Hematology, COVID-19, Merck & Co., Merck, Drug, Pembrolizumab, Annual report, Therapy, SAP, Doctor of Science, Organic Process Research & Development, Baylor University Medical Center, AML, Society, Ovarian cancer, Lymphatic system, SLS, Patient, Pharmaceutical industry, Greater China

NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) --  SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and reported its financial results for the quarter ended September 30, 2022.

Key Points: 
  • ET
    NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (SELLAS or the Company), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and reported its financial results for the quarter ended September 30, 2022.
  • Financial Results for the Third Quarter 2022:
    Licensing revenue: There was no licensing revenue for the third quarter of 2022 or 2021.
  • Acquired In-Process Research and Development: There was no acquired in-process research and development for the third quarter of 2022.
  • About SELLAS Life Sciences Group, Inc. SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.

SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia

Retrieved on: 
Monday, November 14, 2022
Trigger, Clinical trial, CDK9, Memorial Sloan Kettering Cancer Center, Senior, Drug, Acute myeloid leukemia, Drug development, Baylor University Medical Center, WT1, AML, Cancer, GPS, Data, CR2, IND, Regulation of tobacco by the U.S. Food and Drug Administration, Lymphatic system, BAT, Annual report, Mortality, SLS, Therapy, SAP, COVID-19, Research, Death, OS, Doctor of Science, MD, Food, Patient, Risk management, Pharmaceutical industry, Medicine, Greater China

NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced important updates relating to its ongoing Phase 3 open-label registrational clinical trial (the REGAL study) for galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients who have achieved complete remission following second-line salvage therapy (CR2 patients).

Key Points: 
  • Accordingly, the overall duration of the REGAL study is now expected to be longer than initially predicted.
  • Additionally, SELLAS development and commercialization partner for the Greater China territory, 3D Medicines (3DMed), has agreed to participate in the REGAL trial through the inclusion of approximately 20 patients from the Greater China territory.
  • About SELLAS Life Sciences Group, Inc.
    SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.
  • These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties.

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 14, 2022
BRM, Clinical trial, Brain, T-ALL, MYC, Thrombocytopenia, Monocyte, CLL, Safety, Security (finance), Anemia, Research and development, BTK, Prelude, R, Administration, Constipation, Drug resistance, CDK9, SMARCA4, Biotechnology, G&A, Research, Vomiting, NHL, COVID-19, Public expenditure, Incidence, Uveal melanoma, Large-cell lung carcinoma, FDA, Pharmacology, Sarcoma, BH3, CDK, Mesothelioma, Lymphoid neoplasms with plasmablastic differentiation, Hematological Cancer Research Investment and Education Act, Cancer, Pharmacokinetics, IND, MCL1, Fatigue, CD14, Glioma, Breast cancer, PRMT5, Human, SMARCA2, Risk, Nausea, Head, Patient, Pharmaceutical industry, Medical device

WILMINGTON, Del., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent clinical and development pipeline progress.

Key Points: 
  • I believe these programs offer the best chance to improve patient outcomes and I share our investigators excitement in our highly differentiated molecules.
  • Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents, and marketable securities as of September 30, 2022, were $224.0 million.
  • Prelude anticipates that its existing cash, cash equivalents and marketable securities will be sufficient to fund Preludes operations into the fourth quarter of 2024.
  • We expect our research and development expenses to vary from quarter to quarter, primarily due to the timing of our clinical development activities.

SELLAS Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanc

Retrieved on: 
Thursday, November 10, 2022
MSD, FIU Herbert Wertheim College of Medicine, Multiple, Population, GPS, Survival, Canine cancer detection, Company, Memorial Sloan Kettering Cancer Center, DCR, Neoplasm, Clinical trial, Toxic leukoencephalopathy, Tumor microenvironment, Immunotherapy, Pembrolizumab, Merck & Co., SEC, Assistant, Vaccination, Cancer, Overalls, Progression-free survival, Patient, MD, COVID-19, Doctor of Science, WT1, Terminology, Woman, Data, CDK9, GLOBE, PFS, SLS, Clinical Ovarian Cancer & Other Gynecologic Malignancies, OS, Annual report, NASDAQ, Safety, Drug development, Merck Sharp & Dohme Federal Credit Union, Ovarian cancer, TME, NEW, Death, Therapy, ORR, CPS, Medical imaging, Pharmaceutical industry, Greater China, Merck, PD-L1

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced confirmatory top-line clinical data from the final analysis of results from its Phase 1/2 clinical trial of galinpepimut-S (GPS), the Company’s Wilms Tumor-1 (WT1)-targeting peptide immunotherapeutic, in combination with Merck’s anti-PD-1 therapy, pembrolizumab (KEYTRUDA®), in patients diagnosed with WT1(+) relapsed or refractory platinum-resistant advanced metastatic ovarian cancer.

Key Points: 
  • Of the 17 patients, 16 received at least three doses of GPS and had follow-up cross-sectional imaging (CT/MRI) to determine tumor status.
  • Importantly, survival and disease control benefits were observed in patients harboring tumors with any level of detectable PD-L1 expression, i.e., those with Combined Positive Score (CPS) of one or higher.
  • The DCR is 63.6 percent in patients with a CPS of one or higher in this study.
  • These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties.

Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Forward-looking statement, Form 10-K, IND, BCL2, European Medicines Agency, Workforce, Pandemic, Non-Hodgkin lymphoma, Food, Nasdaq, Bortezomib, CLL, Research, Multiple, SME, PALO, COVID-19, Securities Act of 1933, MYC, Regulation of tobacco by the U.S. Food and Drug Administration, SEC, Failure, Control, Goal, Safety, Richter's transformation, BTK, SMDC, NHL, Micro, Securities Exchange Act of 1934, 8-K, EMA, Cancer, B-cell lymphoma, Program, ADC, Chronic lymphocytic leukemia, Treatment, Therapy, Drug Quality and Security Act, Small and medium-sized enterprises, CDK9, Venetoclax, RS, FDA, Pharmaceutical industry, Fine chemical, Risk management, Animal, Patient, Lenalidomide, Bayer

PALO ALTO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • The recent Orphan Drug Designation for enitociclib further strengthens our program by offering important clinical development and commercialization benefits, said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx.
  • Based on its current business plans and assumptions, Vincerx believes its available cash will be sufficient to meet its operating requirements into late 2024.
  • Research and development expenses for the quarter ended September 30, 2022 were approximately $11.1 million, as compared to approximately $12.2 million for the same period in 2021.
  • Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.

Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 9, 2022
All rights reserved, GLOBE, Cell cycle, Lymphatic system, CDK2, BRD4, Lymphoma, Durable, ENA, Pancreatic cancer, Enrollment, Webcast, Research, Risk, Hematology, Large-cell lung carcinoma, R, Annual report, NASDAQ, News, Patient, Safety, Oral, T-cell lymphoma, Company, Cyclacel, Clinical trial, Conference, Liver, ET, Ovarian cancer, CDK9, PLK1, CYCC, COVID-19, Income, Pharmaceutical industry, Fine chemical, Birth control, Broadcasting

We look forward to reporting updated data from our ongoing Phase 1/2 studies of fadraciclib and CYC140 in 2023.

Key Points: 
  • We look forward to reporting updated data from our ongoing Phase 1/2 studies of fadraciclib and CYC140 in 2023.
  • As of September 30, 2022, cash and cash equivalents totaled $23.7 million, compared to $36.6 million as of December 31, 2021.
  • Copyright 2022 Cyclacel Pharmaceuticals, Inc. All Rights Reserved.
  • The Cyclacel logo and Cyclacel are trademarks of Cyclacel Pharmaceuticals, Inc.

Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, Review, Private Securities Litigation Reform Act, Forward-looking statement, Investment, U.S. Securities and Exchange Commission, PK, Nasdaq, Research, Risk, FLT3, Conference call, MYC, SEC, Degenerative disease, Patient, Safety, Time, Breast, Drug, Cancer, SYK, Program, AML, Factor X, Conference, NPM1, Therapy, Security (finance), KRON, CDK9, MLL, COVID-19, PD, Pharmaceutical industry, Medical device, Kronos

Kronos Bio decided to end the trial after its recent review of enrollment data.

Key Points: 
  • Kronos Bio decided to end the trial after its recent review of enrollment data.
  • This prioritization is expected to extend cash runway from the fourth quarter of 2024 into the second quarter of 2025.
  • Kronos Bio remains committed to its SYK inhibitor program and to patients with AML.
  • Kronos Bio is a biopharmaceutical company that is advancing two investigational compounds in clinical trials for patients with cancer.

Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results

Retrieved on: 
Tuesday, November 8, 2022
SAN, GLOBE, Review, Private Securities Litigation Reform Act, Forward-looking statement, Investment, U.S. Securities and Exchange Commission, Nasdaq, Research, Risk, MYC, SEC, Safety, Time, Cancer, D, SYK, AML, Patient, Therapy, Security (finance), KRON, CDK9, PD, Pharmaceutical industry, Lease, Kronos

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and third-quarter 2022 financial results.

Key Points: 
  • After a recent review of enrollment data that projected significant delays, Kronos Bio will discontinue the Phase 3 entospletinib trial and close enrollment in the fourth quarter of 2022.
  • Kronos Bio remains on track to report pharmacokinetic (PK), pharmacodynamic (PD) and safety data, as well as the RP2D, from the Phase 1/2 study of KB-0742 in solid tumors in the fourth quarter of 2022.
  • Kronos Bio is a biopharmaceutical company that is advancing two investigational compounds in clinical trials for patients with cancer.
  • Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass.

SELLAS Life Sciences to Present Data on its Highly Selective CDK9 Inhibitor, GFH009, at the 2022 American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Memorial Sloan Kettering Cancer Center, Company, Therapy, CDK9, Terminology, COVID-19, WT1, Annual report, Drug development, GPS, SEC, Pharmaceutical industry, Greater China

SELLAS lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types.

Key Points: 
  • SELLAS lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types.
  • GPS has potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications.
  • All statements other than statements of historical facts are forward-looking statements, including those relating to future events.
  • These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties.